Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | The efficacy & toxicity of venetoclax-based combination therapies in CLL

Lukas Smolej • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Antibodies Ibrutinib Obinutuzumab Rituximab Venetoclax
ELEVATE CLL TN

Lukas Smolej, MD, PhD, Charles University, Hradec Králové, Czech Republic, comments on the possibility of combining venetoclax with BTK inhibitors or monoclonal antibodies in chronic lymphocytic leukemia (CLL), discussing the efficacy and toxicity of these treatment regimens and their place in the frontline and relapsed/refractory (R/R) setting. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lukas Smolej

2:31
The role of chemoimmunotherapy in the era of targeted therapies for CLL
Lukas Smolej • 7 Oct 2022
1:25
Genomic testing and therapeutic decisions in routine clinical practice in CLL
Lukas Smolej • 7 Oct 2022
1:27
Geriatric assessment techniques in CLL
Lukas Smolej • 7 Oct 2022
1:03
Genomic tests available to patients with CLL at tertiary hospitals
Lukas Smolej • 7 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals